NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Rhea-AI Summary
NanoViricides (NYSE American: NNVC) entered a securities purchase agreement with a single institutional investor for a registered direct offering expected to raise approximately $2 million in gross proceeds.
The deal includes common shares (or pre-funded warrants) plus warrants to purchase 1,333,334 shares at $1.75, expiring three years after issuance. Closing is expected around May 18, 2026.
AI-generated analysis. Not financial advice.
Positive
- Registered direct offering expected to raise approximately $2 million in gross proceeds
- Single fundamental institutional investor participating in the financing
- Warrants exercise price set at $1.75 per share for three years
Negative
- Issuance of new common shares and warrants may dilute existing shareholders
- Additional dilution possible if 1,333,334 warrants are exercised
- Net proceeds will be lower than $2 million after fees and expenses
News Market Reaction – NNVC
On the day this news was published, NNVC declined 14.94%, reflecting a significant negative market reaction. Argus tracked a trough of -16.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $37.58M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, NNVC was up 1.16% while peers showed mixed moves: QTTB +3.82%, XCUR +3.25%, LIXT +1.61%, SABS -2.75%, FBLG -6.90%. Peer_momentum scanner also flagged RNTX and GDTC up and XCUR down, reinforcing stock-specific, not sector-wide, dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Pipeline promotion | Positive | -3.9% | Highlighted global hantavirus risk and NV-387 broad-spectrum potential. |
| May 06 | Conference participation | Neutral | +0.0% | Announced participation and meetings at D. Boral Capital conference. |
| May 04 | Regulatory designation | Positive | +15.4% | NV-387 received US FDA Orphan Drug Designation for measles. |
| Apr 21 | Disease spotlight | Positive | -1.6% | Linked deadly measles outbreaks to need for NV-387 treatment option. |
| Apr 07 | Regulatory application | Positive | +6.9% | Filed Rare Pediatric Disease Drug designation for NV-387 in measles. |
Recent positive pipeline and designation news has sometimes led to gains but also saw occasional sell-offs, indicating mixed follow-through on favorable headlines.
Over the last few months, NanoViricides highlighted NV-387’s progression with Phase I completion, Orphan Drug status, and a Rare Pediatric Disease application, plus disease-outbreak themed updates and a conference appearance. Reactions have varied: the Orphan Drug designation on May 4 saw a +15.38% move, while similarly positive measles and hantavirus narratives on Apr 21 and May 11 produced modest declines. Today’s offering follows a stretch of clinically oriented, mostly constructive news.
Regulatory & Risk Context
An effective Form S-3 shelf dated Dec 15, 2025 registers up to 7,142,858 shares for resale tied to Series A and B warrants. If those warrants are fully exercised for cash, NanoViricides could receive approximately $13.4 million in gross proceeds, separate from this new registered direct offering.
Market Pulse Summary
The stock dropped -14.9% in the session following this news. A negative reaction despite recent clinical and designation milestones fits a pattern where financing needs overshadow pipeline progress. The new registered direct offering for US$2 million, alongside an active S-3 shelf tied to up to $13.4 million in warrant exercises, adds to equity overhang. Prior filings highlighted substantial doubt about going concern, so further weakness could reflect concern over continued dilution and funding risk.
Key Terms
registered direct offering financial
pre-funded warrants financial
warrants financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 1,333,334 million common shares (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares for gross proceeds of approximately US
D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.
The closing of the Offering is expected to occur on or about May 18, 2026, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of ~
The common shares (or pre-funded warrants in lieu thereof) are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333- 271706), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on May 22, 2023.
A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC. Once filed, it will be available on the SEC's website at https://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NanoViricides
NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape. Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD). This could provide 7 years market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is a revolutionary antiviral that we believe will be the drug offered at "first visit" when the patient presents to a doctor with any respiratory viral illness. NV-387 was also found to be highly effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends, and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. These risks include, but are not limited to, the ability to complete the offering on the terms described or at all, the ability to satisfy customary closing conditions, market conditions, regulatory developments affecting the digital asset and stablecoin industries, and other risks described in the Company's filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading "Risk Factors" in the Company's Annual Reports on Form 20-F, as may be supplemented or amended by the Company's Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information, or otherwise.
Contacts
For inquiries, contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
SOURCE: NanoViricides
View the original press release on ACCESS Newswire